NASDAQ:NUVA NuVasive (NUVA) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free NUVA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$39.75▼$39.7550-Day Range$38.12▼$40.6652-Week Range$35.17▼$49.53VolumeN/AAverage Volume1.16 million shsMarket Capitalization$2.08 billionP/E Ratio79.50Dividend YieldN/APrice Target$51.33 Stock AnalysisStock Analysis Get NuVasive alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About NuVasive Stock (NASDAQ:NUVA)NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… NUVA Stock News HeadlinesMarch 13, 2024 | msn.comUK reinstates modified MAGEC X system for scoliosis treatmentsMarch 12, 2024 | finance.yahoo.comOrthobiologics Market Set to Reach $8.2 Billion by 2030, Viscosupplementation Segment Exhibiting Robust GrowthMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 12, 2024 | finanznachrichten.deMinimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarketsMarch 5, 2024 | finance.yahoo.comJ. Kurt Jacobus, Ph.D. Joins CurvaFix Board of DirectorsFebruary 21, 2024 | uk.finance.yahoo.comQ4 2023 Globus Medical Inc Earnings CallFebruary 21, 2024 | markets.businessinsider.comGlobus Medical: Hold Rating Affirmed Amidst Modest Growth Projections and Integration RisksFebruary 13, 2024 | markets.businessinsider.comGlobus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference CallMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… February 5, 2024 | finance.yahoo.comGlobus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial OfficerJanuary 26, 2024 | finance.yahoo.comGlobus lays off Nuvasive employees after mergerJanuary 25, 2024 | finanznachrichten.deCoherent Market Insights: Global Sacroiliac Joint Fusion Market to Reach US$ 1,525.1 Million by 2030, Rising at a CAGR of 13.6% | Report by CoherentMIJanuary 25, 2024 | finance.yahoo.comImplanet Announces the Appointment of Max W. Painter as Vice-President and General Manager of its US SubsidiaryJanuary 25, 2024 | finanznachrichten.deSpinal Implants Market Worth $14.3 Billion | MarketsandMarketsJanuary 23, 2024 | finanznachrichten.deSMAIO: 2023 Sales up +120% to €5.4 MillionJanuary 23, 2024 | finance.yahoo.comOrthopedics leaders watch procedure backlog, new technologies in 2024January 23, 2024 | finance.yahoo.comHere's Why You Should Retain Globus Medical (GMED) Stock NowJanuary 17, 2024 | finance.yahoo.comNuvasive’s former CEO joins 3M spinoffJanuary 16, 2024 | finance.yahoo.comAmanda Bloom Joins Spineology as Executive Vice President of MarketingJanuary 16, 2024 | finance.yahoo.comLimbplastX Will Be One Of The Few Sites To Receive Nuvasive’s Exclusive Brand-New Precice Max Nail On February 26thJanuary 8, 2024 | finance.yahoo.comOrthofix Provides Executive Management Business Update and Appoints Julie Andrews as Chief Financial OfficerDecember 27, 2023 | msn.comFormer Buckeye Branden Bowen survived 'rough' time, now is 'really excited for the future'December 26, 2023 | bizjournals.com2023 in Review: Challenging year in health care brings surge of mergers and acquisitionsNovember 8, 2023 | markets.businessinsider.comPositive Outlook for Globus Medical Post-Merger: Analysis of Q3 Results and Future PlansNovember 8, 2023 | markets.businessinsider.comHold Rating on Globus Medical: An Assessment of the NuVasive Deal and Updated Financial ProjectionsNovember 7, 2023 | finance.yahoo.comGlobus Medical Reports Third Quarter 2023 ResultsNovember 6, 2023 | thestreet.comNuVasive Stock Hits New 52-Week Low (NUVA)See More Headlines Receive NUVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/02/2023Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Devices Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:NUVA CUSIP67070410 CIK1142596 Webwww.nuvasive.com Phone(858) 909-1800Fax800-475-9134Employees3,000Year Founded1997Price Target and Rating Average Stock Price Target$51.33 High Stock Price Target$58.00 Low Stock Price Target$45.00 Potential Upside/Downside+29.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.50 Trailing P/E Ratio79.50 Forward P/E Ratio17.91 P/E GrowthN/ANet Income$40.41 million Net Margins2.32% Pretax Margin3.41% Return on Equity12.17% Return on Assets4.88% Debt Debt-to-Equity Ratio0.50 Current Ratio1.25 Quick Ratio0.65 Sales & Book Value Annual Sales$1.23 billion Price / Sales1.70 Cash Flow$4.96 per share Price / Cash Flow8.01 Book Value$17.02 per share Price / Book2.34Miscellaneous Outstanding Shares52,449,000Free Float52,171,000Market Cap$2.08 billion OptionableOptionable Beta1.07 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. J. Christopher Barry (Age 50)CEO & Director Comp: $3.08MMr. Matthew K. Harbaugh (Age 53)Principal Accounting Officer, CFO & Exec. VP Comp: $1.37MMr. Dale A. Wolf (Age 43)Sr. VP of Global Operations Comp: $782.6kMr. Nathaniel B. Sisitsky Esq. (Age 48)Sr. VP, Gen. Counsel & Corp. Sec. Comp: $842.84kMr. Michael Farrington (Age 39)Sr. VP of People & Culture Comp: $626.46kMr. Ryan DonahoeSr. VP & Chief Technology OfficerMs. Juliet C. CunninghamVP of Investor RelationsMr. Sean FreemanSr. VP of Strategy & Corp. Devel.Ms. Lisa PecoraVP & Head of Global Commercial Fin.Ms. Aviva McPherronSr. VP of Information TechnologyMore ExecutivesKey CompetitorsICU MedicalNASDAQ:ICUIInari MedicalNASDAQ:NARIEargoNASDAQ:EARSana BiotechnologyNASDAQ:SANAAmphastar PharmaceuticalsNASDAQ:AMPHView All Competitors NUVA Stock Analysis - Frequently Asked Questions Should I buy or sell NuVasive stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVA shares. View NUVA analyst ratings or view top-rated stocks. What is NuVasive's stock price target for 2024? 2 brokerages have issued twelve-month target prices for NuVasive's stock. Their NUVA share price targets range from $45.00 to $58.00. On average, they predict the company's share price to reach $51.33 in the next twelve months. This suggests a possible upside of 29.1% from the stock's current price. View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts. How were NuVasive's earnings last quarter? NuVasive, Inc. (NASDAQ:NUVA) issued its quarterly earnings results on Wednesday, August, 2nd. The medical device company reported $0.56 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.56. The medical device company had revenue of $317.80 million for the quarter, compared to the consensus estimate of $322.53 million. NuVasive had a net margin of 2.32% and a trailing twelve-month return on equity of 12.17%. The company's revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period last year, the company earned $0.47 earnings per share. What ETFs hold NuVasive's stock? ETFs with the largest weight of NuVasive (NASDAQ:NUVA) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), ProShares Merger ETF (MRGR), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Vanguard S&P Small-Cap 600 Value ETF (VIOV), SPDR S&P 600 Small CapValue ETF (SLYV), iShares S&P Small-Cap 600 Value ETF (IJS) and Syntax Stratified SmallCap ETF (SSLY). What is Chris Barry's approval rating as NuVasive's CEO? 59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees. What other stocks do shareholders of NuVasive own? Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT). Does NuVasive have any subsidiaries? The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.Read More This page (NASDAQ:NUVA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuVasive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.